Podcast

Managing Patients with HFrEF Post-Discharge: Discussion of the Latest Evidence

Launch Date
10/04/2021
Credit Amount
0.00 Expired
Credit Expires
10/04/2022

Faculty

Javed Butler, MD, MPH, MBA
Patrick H. Lehan Chair in Cardiovascular Research, Professor and Chairman, Department of Medicine
Professor of Physiology, University of Mississippi Medical Center, Jackson, MS
Javed Butler, MD, MPH, MBA

Javed Butler, MD, MPH, MBA, is the Patrick H. Lehan Chair in Cardiovascular Research, and Professor and Chairman of the Department of Medicine at the University of Mississippi Medical Center in Jackson, Mississippi. He is also a Professor of Physiology. Prior to joining the University of Mississippi, he was Charles A. Gargano Professor and Director of the Division of Cardiovascular Medicine and Co-Director of the Heart Institute at Stony Brook University, New York. He had served as the director for heart failure research at Emory University and director of the heart and heart-lung transplant programs at Vanderbilt University prior to that.

He received his medical degree from the Aga Khan University and then completed residency training at Yale University, cardiology fellowship, and advanced heart failure, and transplant fellowships at Vanderbilt University, and cardiac imaging fellowship at the Massachusetts General Hospital at the Harvard Medical School. He received his Master of Public Health Degree from Harvard University and Masters in Business Administration from Emory University.

Dr. Butler is board certified in cardiovascular medicine, advanced heart failure, and transplant medicine. His research interests focus on clinical trials in patients with heart failure. He serves on several national committees for the American College of Cardiology, American Heart Association, National Institutes of Health, U.S. Food & Drug Administration, and the Heart Failure Society of America. He is the recipient of the Simon Dack Award by the American College of Cardiology as well as the Time, Feeling, and Focus Award by the American Heart Association.

Dr. Butler has authored more than 700 peer-reviewed publications. He serves on the editorial board of several peer reviewed cardiovascular journals. He has been cited numerous times in America’s Best Doctors list.

Alanna Morris, MD, MSc, FHFSA, FACC, FAHA
Associate Professor of Medicine, Division of Cardiology, Emory University School of Medicine
Director of Heart Failure Research, Emory University Clinical Cardiovascular Research Institute, Atlanta, GA
Alanna Morris, MD, MSc, FHFSA, FACC, FAHA

Dr. Alanna A. Morris is an Associate Professor of Medicine in the Division of Cardiology at Emory University School of Medicine and the Emory Cardiovascular Clinical Research Institute. Currently she serves as the Director for Heart Failure Research and the Associate Program Director for the Clinical Investigator Track of the Cardiology Fellowship. Dr. Morris received her undergraduate degree in Biology from Xavier University of Louisiana, and her medical degree from the Harvard Medical School. She completed her residency at Brigham and Women’s Hospital in Boston, Massachusetts. Subsequently, she came to Emory University to complete fellowships in general cardiology, and advanced heart failure, and transplant. Her clinical time is spent as faculty in Emory’s Center for Heart Failure Therapy and Transplantation. She has held K23 funding from the NIH/NHLBI, and career development award funding from the Robert Wood Johnson Foundation Harold Amos Faculty Development Program. Her research program focuses on studying mechanisms that underlie race- and gender disparities in heart failure risk and progression, including the role of biologic determinants such as biomarkers of oxidative stress and endothelial dysfunction, as well as social determinants of health including neighborhood that amplify risk for adverse outcomes in heart failure.

Explore By Section
Statement of Need Learning Objectives Financial Support Target Audience Credit Information Disclosure Declaration Obtaining Credit

Statement of Need

In 2021, new practice guidelines, updated clinical pathways, and a universal definitions and classification document were released to help clinicians better diagnose, stage, and manage patients with heart failure (HF). The recommendations include direction on sequencing foundational therapies and integrating the latest FDA-approved additions to the HF armamentarium – SGLT2 inhibitors and an oral sGC stimulator–for patients with HF with reduced ejection fraction (HFrEF).

In this first of two episodes in the CMEOCast HF podcast series, an expert faculty, including a member of the writing committee for several of the new guidelines, provides insightful perspectives on implementing the new recommendations in practice, including risk stratification, staging/classification, the role of biomarkers, therapeutic sequencing, relevant guidelines and study results. Additionally, faculty discuss helpful apps available for risk stratification and treatment decision-making support.

Learning Objectives

At the end of this CME/CE activity, participants should be able to:

  • Integrate a risk stratification tool into practice for assessment of patients with HFrEF.
  • Implement treatment strategies for HFrEF that reflect updated guidelines and study results.

Financial Support

Supported by an educational grant from Merck Sharp & Dohme Corp.

Target Audience

Cardiologists, Primary Care Physicians, PAs, Nurse Practitioners, Nurses, Pharmacists

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians (ACCME) 0.5

CME Outfitters, LLC, designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC) 0.5

This activity is designated for 0.5 contact hours.

Pharmacists/Pharmacy Tech (ACPE) 0.5

This application-based activity is approved for 0.5 contact hours (0.05 CEUs) of continuing pharmacy credit.
JA0007185-0000-21-012-H01-P

PAs (AAPA) 0.5

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until expiration date listed above. PAs should only claim credit commensurate with the extent of their participation.

ABIM MOC 0.5

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Butler reports that he is on the speakers bureau for AstraZeneca; Boehringer Ingelheim (BI)-Lilly Alliance; Janssen Pharmaceuticals, Inc.; and Novartis Pharmaceuticals Corporation. He is a consultant for Abbott; Adrenomed; Amgen Inc.; Applied Therapeutics; Array BioPharma Inc.; AstraZeneca; Bayer; Boehringer Ingelheim; CVRx; G3 Pharmaceuticals; Impulse Dynamics; Innolife Pharma, Inc.; Janssen Pharmaceuticals, Inc; LivaNova; Luitpold Pharmaceuticals, Inc.; Medtronic; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novo Nordisk; Relypsa, Inc.; Sequanna Medical; and Vifor Pharma, Inc..

Dr. Morris reports that she receives research support from the Association of Black Cardiologists; National Institutes of Health/National Heart Lung, and Blood Institute; and the Robert W. Woodruff Foundation, Inc. She also reports Institutional Research Support (paid to Emory University): Alnylam Pharmaceuticals; Amgen Inc.; Boston Scientific Corporation; Eidos Therapeutics; Ionis; Merck & Co., Inc.; MyoKardia, Inc.; National Heart, Lung, and Blood Institute (NHLBI); and Pfizer Inc. She is a shareholder with direct purchase with Gilead Sciences, Inc.

 

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report:

  • Warren Beckman (planning committee)
  • Evan Luberger (planning committee)
  • Jan Perez (planning committee)
  • Sharon Tordoff (planning committee)
  • Jeffrey Hefland, DO (Peer Reviewer)

CME Outfitters, LLC and the faculty do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit https://www.cmeoutfitters.com/privacy-and-confidentiality-policy.

Questions about this activity?

Call us at (877) CME-PROS or (877) 263-7767.

PD-070-100421-44

Related Activities

Cardiology
12/28/2022

Immune Checkpoint Inhibitor Cardiotoxicity: Contributing Factors, Appropriate Treatments, and Retreatment Options

1.0
Begin Learn More
Cardiology
12/29/2022

Cardiology: Real-World Tactics to Address Health Inequities

0.75
Begin Learn More
TV-125-071421-57
Cardiology
07/14/2021

Call to Action for Health Equity: Racial Disparities in the Care of Patients with Cardiometabolic Disease

1.5
Begin Learn More
Managing Patients with HFrEF Post-Discharge: Discussion of the Latest Evidence
Event Date: 10/04/2021
Begin